Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mineralocorticoid Receptor and Cardiovascular Disease
Mathieu Buonafine, Benjamin Bonnard, Frédéric Jaisser
American Journal of Hypertension (2018) Vol. 31, Iss. 11, pp. 1165-1174
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 23, pp. 2219-2229
Open Access | Times Cited: 1749
Inflammation in Heart Failure
Sean Murphy, Rahul Kakkar, Cian P. McCarthy, et al.
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 11, pp. 1324-1340
Open Access | Times Cited: 442
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, et al.
Circulation (2020) Vol. 143, Iss. 6, pp. 540-552
Open Access | Times Cited: 223
Therapeutic Advances in Diabetic Nephropathy
Hanny Sawaf, George Thomas, Jonathan J. Taliercio, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 2, pp. 378-378
Open Access | Times Cited: 87
New progress in drugs treatment of diabetic kidney disease
Junmin Wang, Hongjiao Xiang, Yifei Lü, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111918-111918
Open Access | Times Cited: 56
Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
Jonatan Barrera‐Chimal, Benjamin Bonnard, Frédéric Jaisser
Annual Review of Physiology (2022) Vol. 84, Iss. 1, pp. 585-610
Closed Access | Times Cited: 53
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms
Murray Epstein, Csaba P. Kövesdy, Catherine M. Clase, et al.
American Journal of Kidney Diseases (2022) Vol. 80, Iss. 5, pp. 658-666
Open Access | Times Cited: 47
Cardiorenal benefits of finerenone: protecting kidney and heart
José Ramón González–Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 31
An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction
Jianyong Sun, Lin‐Juan Du, Xuerui Shi, et al.
Science Advances (2023) Vol. 9, Iss. 14
Open Access | Times Cited: 28
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong‐Lim Kim, Seung‐Eun Lee, Nan Hee Kim
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 43-55
Open Access | Times Cited: 27
Biomarkers to Guide Medical Therapy in Primary Aldosteronism
Gregory L. Hundemer, Alexander A. C. Leung, Gregory Kline, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 69-94
Open Access | Times Cited: 26
The Role of Cyclic AMP Signaling in Cardiac Fibrosis
Marion Delaunay, Halima Osman, Simon Kaiser, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 69-69
Open Access | Times Cited: 67
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 125-134
Open Access | Times Cited: 51
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
Alberto Ortíz, Charles J. Ferro, Olga Balafa, et al.
Nephrology Dialysis Transplantation (2021) Vol. 38, Iss. 1, pp. 10-25
Open Access | Times Cited: 48
Endothelial and vascular smooth muscle dysfunction in hypertension
Mariana G. de Oliveira, Wilson Nadruz, Fabíola Z. Mónica
Biochemical Pharmacology (2022) Vol. 205, pp. 115263-115263
Closed Access | Times Cited: 36
The Effect of Aldosterone on Cardiorenal and Metabolic Systems
Hiromasa Otsuka, Masanori Abe, Hiroki Kobayashi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5370-5370
Open Access | Times Cited: 21
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study
Gregory L. Hundemer, Mohsen Agharazii, François Madore, et al.
Circulation (2023) Vol. 149, Iss. 2, pp. 124-134
Closed Access | Times Cited: 19
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
Shweta Bansal, Maria Eugênia Fernandes Canziani, Rita Birne, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e076444-e076444
Open Access | Times Cited: 7
Nuclear receptors in podocyte biology and glomerular disease
Shipra Agrawal, John Cijiang He, Pierre‐Louis Tharaux
Nature Reviews Nephrology (2020) Vol. 17, Iss. 3, pp. 185-204
Closed Access | Times Cited: 46
MiRNA‐181a is a novel regulator of aldosterone–mineralocorticoid receptor‐mediated cardiac remodelling
Ankita Garg, Ariana Foinquinos, Mira Jung, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 8, pp. 1366-1377
Open Access | Times Cited: 40
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
Edgar V. Lerma, Daniel J. Wilson
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 5, pp. 501-513
Open Access | Times Cited: 26
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
Peter Kolkhof, Robert Lawatscheck, Gerasimos Filippatos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9243-9243
Open Access | Times Cited: 25
The impact of combination of zofenopril and different diuretics on regression of myocardial reperfusion injury and oxidative status in spontaneously hypertensive rats
Maja Savić, Nevena Dragasevic, Jasmina Sretenovic, et al.
Molecular and Cellular Biochemistry (2025)
Closed Access
Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
Mariana Morais David Pliças, Bernardo Marques da Silva, Edgar Almeida
Nefrología (English Edition) (2025) Vol. 45, Iss. 3, pp. 214-227
Open Access
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
Richard Hobbs, Richard J. McManus, Clare Taylor, et al.
Health Technology Assessment (2025), pp. 1-130
Open Access
Page 1 - Next Page

Scroll to top